News + Analysen
News + Adhoc
zugeh. Wertpapiere
Strukturierte Produkte
31.01.2023 20:00:00

This Discount Growth Stock Is a Once-in-a-Decade Buying Opportunity Right Now

Moderna (NASDAQ: MRNA) soared to fame -- and generated billions of dollars in profit -- thanks to its coronavirus vaccine. The biotech company also brought big gains to early investors. The stock climbed 1,200% from the start of 2020 through the end of the following year.The company's stock market winning streak ended last year, though, when investors started worrying about post-pandemic revenue. And that left Moderna's shares down more than 60% from their peak. Some may say Moderna's moment in the spotlight is over. But a good look at the company's pipeline and vaccine market predictions tells a different story. And that means this cheap growth stock offers you a once-in-a-decade buying opportunity right now. First, a quick word on Moderna's path so far. The company generated $17.7 billion in vaccine revenue in 2021. And it expects to report $18.4 billion for 2022. The bad news is Moderna's vaccine may not be able to replicate these levels in a post-pandemic environment.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"


Viele Anleger setzen deshalb auf den Aktiv verwalteten Global Inflation Protection Basket. Informieren Sie sich über die breit gestreute Auswahl an robusten Aktien & ETFs.